Page 1

amneal Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS -Q2 2021 Net Revenue of $ 535 million ; GAAP Net Income of $ 15 million ; Diluted Income per Share of $ 0.10 - ( 1 ) - Adjusted EBITDA of $ 151 million ; Adjusted Diluted EPS ( 1 ) of $ 0.25 - Maintaining 2021 Full Year Financial Outlook- BRIDGEWATER , NJ , August 9 , 2021 - Amneal Pharmaceuticals , Inc. ( NYSE : AMRX ) ( the " Company " ) announced its results today for the second quarter ended June 30 , 2021 . " Our strong second quarter results reflect the durability and diversity of our business . At a time when drug prices are rising and more people are seeking affordable health care solutions , we are proud to consistently be first or second to market with new and complex generic drugs . Together with our robust pipeline of specialty products , this quarter we achieved Amneal's highest level of net revenues with adjusted EBITDA reaching its highest level since 2018. Our talented teams are innovating and executing well and we are excited about the opportunities to come , " said Chirag and Chintu Patel , Co - Chief Executive Officers . Net revenue in the second quarter of 2021 was $ 535 million , an increase of 15 % compared to $ 465 million in the second quarter of 2020. The increase was driven by Generic product launches , growth in our promoted Specialty products RytaryⓇ and Unithroid® , and overall volume growth within our Generics and AvKARE segments . Net income attributable to Amneal Pharmaceuticals , Inc. was $ 15 million in the second quarter of 2021 compared to a net loss of $ 12 million in the second quarter of 2020. The increase in net income was primarily attributable to growth in net revenue and gross profit , which was driven by strong gross margin improvement in our Generics segment . Adjusted EBITDA ( 1 ) in the second quarter of 2021 was $ 151 million , an increase of 50 % compared to the second quarter of 2020 , reflective of net income growth . Adjusted diluted EPS ( ¹ ) in the second quarter of 2021 was $ 0.25 , an increase of 92 % from $ 0.13 in the second quarter of 2020 , reflective mostly of growth in adjusted EBITDA ( ¹ ) . ( 1 ) See " Non - GAAP Financial Measures " below . Maintaining Full Year 2021 Financial Outlook Amneal is maintaining its previously provided guidance . Net revenue Adjusted EBITDA ( 1 ) Adjusted diluted EPS ( 2 ) Operating cash flow Capital expenditures Weighted average diluted shares outstanding ( 3 ) ( 1 ) Includes 100 % of EBITDA from the AvKARE acquisition . ( 2 ) Accounts for 35 % non - controlling interest in AvKARE and reflects the current federal tax rate of 21 % . Full Year 2021 Financial Guidance $ 2.1 billion $ 2.2 billion $ 500 million $ 540 million $ 0.70 - $ 0.85 $ 220 million $ 250 million $ 60 million $ 70 million Approximately 303 million ( 3 ) Assumes the weighted average diluted shares outstanding of class A and class B common stock under the if - converted method . 1